Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Up 94.9% in July

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 522,716 shares, an increase of 94.9% from the July 15th total of 268,144 shares. Based on an average trading volume of 1,354,099 shares, the short-interest ratio is currently 0.4 days. Currently, 0.0% of the shares of the stock are sold short.

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY opened at $13.84 on Monday. The stock has a market cap of $54.39 billion, a P/E ratio of -27.14, a price-to-earnings-growth ratio of 4.34 and a beta of 0.55. Bayer Aktiengesellschaft has a 1 year low of $7.48 and a 1 year high of $15.23. The stock’s 50-day moving average price is $13.03 and its two-hundred day moving average price is $12.17. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.06. The business had revenue of $12.53 billion for the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 17.00%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, equities analysts predict that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current year.

Analyst Ratings Changes

BAYRY has been the topic of several research reports. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. Deutsche Bank Aktiengesellschaft raised Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Finally, Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.